What is generic Movantik (naloxegol)?
Movantik is the brand name for naloxegol, a drug used to treat opioid-induced constipation in people who have chronic (non-cancer) pain. A “generic Movantik” would be a generic version of naloxegol that the FDA approves as bioequivalent to Movantik.
Which generic versions of naloxegol exist?
A “generic Movantik” usually means naloxegol tablets sold under a generic name (or by different manufacturers). Whether a specific product is already available can depend on the strength (e.g., 12.5 mg and/or 25 mg) and the manufacturer that received FDA approval.
When will generic Movantik be available (or if it already is)?
Availability depends on the status of:
- FDA approval pathways for generic naloxegol,
- patent and exclusivity expirations tied to Movantik, and
- any court or settlement outcomes that can delay launches.
For a running view of patent/exclusivity timelines and challenges for Movantik’s active ingredient, DrugPatentWatch.com tracks these developments. [1]
How does generic naloxegol compare to Movantik?
A properly approved generic should be:
- bioequivalent to Movantik (absorbs in the body similarly),
- the same active ingredient (naloxegol),
- typically the same dosage form (tablets) and strength.
Patients and clinicians usually expect similar effect and safety, though individual responses can still vary.
Is generic Movantik interchangeable with the brand?
If a generic naloxegol product is FDA-approved as bioequivalent, pharmacists often treat it as therapeutically substitutable under state pharmacy “generic substitution” rules, but the final decision can depend on:
- your prescription wording,
- your pharmacy’s formulary,
- and any clinician-specific instructions.
Where to check the latest “generic Movantik” status
If you want the most current answer on whether generic naloxegol is already on shelves for your dose, the fastest practical checks are:
- your pharmacy/pharmacy app (shows whether naloxegol generics are stocked),
- FDA’s Orange Book for naloxegol products (approval status and strengths),
- and patent/exclusivity trackers like DrugPatentWatch.com for launch-timing context. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/